Research Medical Center
June 19, 2017

The Blood Cancer Center of the Sarah Cannon Cancer Institute HCA Midwest Health, located at Research Medical Center, announces that Suman Kambhampati, M.D., board-certified in Hematology/Medical Oncology, has joined as Co-Medical Director. Kambhampati treats patients affected by blood cancers and complex hematology issues and has led or participated in multiple cancer research studies and published numerous professional papers.  The program provides comprehensive outpatient services and a dedicated inpatient oncology unit designed to care for patients with complex malignant blood disorders including leukemia, lymphoma and myeloma.

In addition to Kambhampati, The Blood Cancer Center’s accomplished care team of blood cancer specialists providing compassionate, high-quality cancer care include Co-Medical Director Frank Slovick, M.D., board certified in Hematology/Medical Oncology; Jaswinder Singh, M.D., board certified medical oncologist and hematologist; Julie Wilhauk, DNP, APRN, AOCNP, nurse practitioner; and a staff of cancer certified nurses. Research Medical Center is part of HCA Midwest Health, Kansas City’s leading healthcare and cancer care provider.

Currently Kambhampati serves as Vice-Chair of the Sarah Cannon Blood Cancer Network (SCBCN) Quality Management Committee on Complex Blood Cancers and is involved with teaching and training of medical residents at the Kansas City VA Medical Center where he is a staff physician. Kambhampati is Principal Investigator with the Southwest Oncology Group (SWOG), an affiliate of the National Cancer Institute (NCI), and leads efforts at VA to enroll patients into SWOG/NCI-sponsored clinical trials.

Kambhampati is recipient of multiple awards for both his research and patient care, including the prestigious Alpha Omega Alpha and Lauri Stauss Leukemia Foundation Research Fellow; Department of Veterans Affairs Special Contribution Awards in Clinical Practice, Research and System Redesigns; Kansas NIH COBRE First Award in Cancer Experimental Therapeutics; Kansas City Super Docs in Hematology and Oncology; Appreciation of Exceptional Leadership and Dedication to Oncology from the Association of VA Hematology and Oncology. He is a professional member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and the Association of Veteran Affairs Hematology & Oncology (AVAHO), of which he served as president.  He serves as board member of the Leukemia and Lymphoma Society (LLS).   

“It is my distinct honor to join The Blood Cancer Center of Sarah Cannon Cancer Institute at Research Medical Center, a program committed to providing an unparalleled experience for patients seeking treatment for blood cancer,” Kambhampati says. “These patients have very unique needs, requiring care from a highly specialized team with access to new therapies.”

The Blood Cancer Center at Research Medical Center builds upon Sarah Cannon HCA Midwest Health’s reputation in cancer by delivering expanded treatment and research options for our patients,” says Slovick. “Our combined efforts and passion will ensure that blood cancer patients across the region have better access to the most innovative, cutting-edge and personalized care throughout the cancer treatment journey and is another example of how Sarah Cannon HCA Midwest Health has invested in our community. And our care team is unparalleled, especially with the addition of Dr. Kambhampati.”

The Blood Cancer Center offers the latest advancements in treatment including clinical trials and immunotherapies from the internationally renowned Sarah Cannon Cancer Institute, one of the leading providers of blood and marrow transplants in the world, providing local access to innovative clinical research trials, tumor profiling and genetic counseling. Additionally, The Blood Cancer Center of Sarah Cannon Cancer Institute offers an Oncology Alert Patient Care Program, the only program in the region that focuses on promptly identifying and treating immunocompromised cancer patients arriving through the Emergency Room.  The mission of the Blood Cancer Center is to ensure patients with blood disorders have convenient access to compassionate state-of-the-art care.

Sarah Cannon, an internationally recognized and highly respected name in cancer, and HCA Midwest Health launched an integrated cancer initiative in 2014 to fulfill the mission of advancing science and transforming cancer care in the region. Through this collaboration, Sarah Cannon Cancer Institute HCA Midwest Health has expanded clinical programs and treatment options, developed physician-led centers of excellence and provides patients access to world-class clinical trials.

For more information on The Blood Cancer Center of the Sarah Cannon Cancer Institute HCA Midwest Health, located at Research Medical Center, and the full spectrum of comprehensive cancer services offered by HCA Midwest Health’s hospitals, including diagnosis, treatment, clinical trials and after care, visit